The Efficacy of Eicosapentaenoic acid Supplementation on the Serum Levels of Homocysteine and Malondialdehyde in the Patients with Type 2 Diabetes Mellitus

摘要

Background: The major cause of mortality among diabetic patients is cardiovascular diseases . The high plasma or serum levels of homocysteine and malondialdehyde are known as modifiable risk factors for CVDs. EPA has the antioxidant, antiinflammatory, antithrombogenic, and antiarteriosclerotic properties. Therefore, we investigated the effect of EPA supplementation on the serum levels of Hcy and MDA in the diabetic patients. Methods: This study was designed as a randomized, double-blind, and placebo-controlled clinical trial. Thirty six patients with type 2 diabetes were given written; informed consent, randomly were classified into 2 groups. They were supplemented with 2 g/day of the capsules of EPA or placebo. Blood sample for measurement of the serum levels of Hcy , MDA , and lipids, as well as FBS and HbA1c were given . Results: The patients supplemented with EPA showed a significant decrease in the serum levels of Hcy and MDA. There were no significant differences between the two groups regarding any demographic, clinical or biochemical data, total energy intake, and macronutrient intake at the baseline, and during the intervention, except for a significant increase of protein intake and the levels of HbA1c in the placebo group, and a significant increase of HDL-c, as well as a slight reduce of total cholesterol, LDL-c, TG and FBS in the supplement group. Conclusions: EPA is atheroprotective via decrease in the serum levels of Hcy and MDA, as well as change in the serum levels of lipids, FBS and HbA1c.